Affiliation:
1. Marc L. Berger, LLC
2. Viatris (United States)
3. Brandeis University
Abstract
Abstract
Background: Adoption and use of RWD for decision-making has been complicated by concerns regarding whether RWD was fit-for-purpose or was of sufficient validity to support the creation of credible RWE. This has greater urgency as regulatory agencies begin to use real world evidence (RWE) to inform decisions about treatment effectiveness.
Methods: We developed a practical screening tool to assess the quality of RWD sources using the framework of Modern Validity Theory. While there has been some convergence of conceptual frameworks, consensus has yet to emerge regarding how to specifically evaluate whether RWD is reliable and fit-for-purpose. We developed a screening tool consistent with the current frameworks and how researchers generally evaluate existing RWD sources for research that they intend to submit to regulatory agencies.
Results: The tool has five dimensions: authenticity, transparency, relevance, accuracy, and reliability. Based upon these dimensions, we developed what more detailed information should be sought by researchers to screen potential RWD sources.
Conclusions: Using a hypothetical example of a medical claims data source, we showed that responding to the tool would not require an extraordinary burden or a lengthy document. This RWD screening tool, which is ready for immediate use, is consistent with current conceptual frameworks to assess whether RWD is fit-for-purpose and adds the additional consideration of experience with RWD sources consistent with Modern Validity Theory.
Publisher
Research Square Platform LLC
Reference45 articles.
1. Arlett, P., DARWIN EU (Data Analytics and Real World Interrogation Network):, Available online: (2020). https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-darwin-eu-data-analytics-real-world-interrogation-network-parlett-ema_en.pdf (Accessed on May 31, 2023)
2. Real-world evidence in EU Medicines regulation: Enabling Use and Establishing Value;Arlett P;Clin. Pharmacol. Ther.,2021
3. Contributions of Real-World Evidence in European Agency’s Regulatory Decision Making;Bakker E;Clin. Pharmacol. Ther.,2022
4. Optimizing the Leveraging of Real World Data: How It Can Improve the Development and Use of Medicines;Berger ML;Value in Health,2015
5. How can we make more rapid progress in the leveraging of real-world evidence by regulatory decision makers?;Berger ML;Value in Health,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献